Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

PRECISE — a personalized suicide-prevention program using daily mood and behavior data

Official title: Development of PRECISE: A Data Driven Personalized Suicide Prevention Intervention

Run by University of California, San Diego · NCT06809348 · Data updated 2026-11-12

This project will test whether using frequent mood and behavior tracking plus tailored coaching and safety planning can help reduce suicidal thoughts in adults at high risk.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment70 (estimated)
SponsorUniversity of California, San Diego
Academic / other
Locations1 site (San Diego, California)
StatusRecruiting
StartedNovember 14, 2025
Main results expectedMarch 2030
Study endsMarch 2030
Registry record updatedApril 29, 2026
Trial IDNCT06809348 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults ages 18–65 who can read English, are willing to share contact information for safety planning, and currently report active suicidal ideation or a recent suicide attempt are the intended participants.

Probably not a fit

People who recently completed Dialectical Behavior Therapy, have moderate to severe substance use disorder in the past 30 days, have dementia or major cognitive impairment, lack capacity to consent, or cannot attend the San Diego site are unlikely to benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PRECISE is a personalized intervention that combines intensive longitudinal (ecological momentary) data with idiographic network analysis to tailor safety plans and skills drawn from Dialectical Behavior Therapy. Participants provide repeated momentary reports of emotions and behavior, and those data are used to identify each person's key triggers and coping targets. Coaches then use those individualized results to adapt safety planning and teach specific coping skills over the intervention period. The approach is being refined and tested at the University of California, San Diego with adults who report recent active suicidal ideation.

Why it matters

Potential benefit: If successful, PRECISE could make safety planning and coping skills more effective by targeting the specific, moment-to-moment risk patterns of each person, potentially reducing suicidal thoughts and behaviors.

How similar studies have gone: Safety planning and DBT skills have shown effectiveness for suicide prevention, and using EMA-driven personalization is a promising but still novel approach with limited direct trial evidence to date.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18-65 years old
* Endorsement of active suicidal ideation on the Columbia Suicide Severity Rating Scale (\>2 or past month thoughts of killing self or attempt in past month)
* English fluency
* Willingness to provide contact information for a key information to be contacted as part of our risk and safety plan.

Exclusion Criteria:

* Past year exposure to DBT
* Moderate/severe substance use disorder within the past thirty days
* Dementia, mild cognitive impairment and/or traumatic brain injury
* Lack of capacity to consent to research and/or under conservatorship.

Where it's running

  • 8980 Villa La Jolla Drive
    San Diego, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.